Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00205400
First received: September 13, 2005
Last updated: August 16, 2013
Last verified: August 2013

September 13, 2005
August 16, 2013
August 1999
March 2005   (final data collection date for primary outcome measure)
Percent time in therapeutic range (TTR) using modified version of Rosendaal method
Same as current
Complete list of historical versions of study NCT00205400 on ClinicalTrials.gov Archive Site
Event rates for thromboembolism, hemorrhages, hospitalizations, urgent care visits, emergency department visits, triage calls, INRs greater than 6.0 and quality of life
Same as current
Not Provided
Not Provided
 
Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care
Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care

Hypothesis: Does the time spent within the target INR range differ when patients are managed by AMD or IT models of anticoagulation care?

Experimental Design: The 36-month trial enrolled 192 eligible patients currently receiving chronic warfarin therapy at the William S. Middleton Memorial VA Hospital. Consenting patients are enrolled and randomized to 1 of 2 groups: usual clinic care with face-to-face visits every 4 weeks (AMS model) or clinic visits every 3 months with interim laboratory visits and telephone follow-up every 4 weeks (IT model). At study conclusion, the amount of time the INR is within target range will be compared between the two groups. Thromboembolic and bleeding event rates, patient knowledge, quality of life and healthcare utilization will also be analyzed.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Anticoagulation
  • Thromboembolism
Procedure: medical care delivery model
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
192
Not Provided
March 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • completion of >3 months of warfarin
  • indefinite warfarin therapy

Exclusion Criteria:

  • patients who currently receive >25% of INR determinations per year from local labs
  • extended absences from VA
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00205400
M-1999-0280
Not Provided
Not Provided
University of Wisconsin, Madison
Not Provided
Principal Investigator: Christine Sorkness, Pharm D University of Wisconsin, Madison
University of Wisconsin, Madison
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP